ArticleCureus2025
Hsa-miR-181a-5p Enhances the Chemosensitivity of Breast Cancer Cells to Tamoxifen by Regulation of the OSBPL3/RAS Signaling Pathway.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification and validation of bile exosomal microRNA signatures for diagnosing acute rejection in liver transplant recipients.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite tamoxifen being a broad-spectrum therapeutic agent for breast cancer (BC) management, the emergence of chemoresistance significantly compromises its clinical effectiveness. OSBPL3 has been identified as a metastasis-promoting protein implicated in BC progression, yet the upstream regulatory mechanisms controlling its expression remain poorly understood, particularly regarding microRNA-mediated regulation.
methodsMCF-7 cells underwent lentiviral infection for stable gene modification, followed by transient transfection with hsa-miR-181a-5p mimics (or corresponding negative controls), antisense miR-181a-5p inhibitors (anti-miR-181a-5p), and OSBPL3-specific small interfering RNAs (siRNAs). The direct binding interaction between miR-181a-5p and OSBPL3 was validated using a dual-luciferase reporter system containing wild-type or mutant 3'UTR sequences. Tamoxifen sensitivity was evaluated through functional assessments, including CCK-8 assay, Annexin V-FITC/PI apoptosis assay, and Transwell migration/invasion assays. Gene expression was assessed by Western blot analysis.
resultsOur findings revealed that miR-181a-5p inhibits OSBPL3 expression by specifically targeting the 3'-UTR of OSBPL3. At the pharmacologically active concentration of 5 µM tamoxifen, overexpression of miR-181a-5p led to the suppression of OSBPL3 expression, which in turn inhibited the invasion, migration, and proliferation of BC cells, while increasing their apoptosis. These effects were further enhanced when OSBPL3 was concurrently interfered with. Additionally, knockdown of OSBPL3 in MCF-7 cells resulted in the coordinated downregulation of five positive regulators of RAS signaling, leading to the activation of the RAS signaling pathway.
conclusionsThese results suggested that the upregulation of miR-181a-5p enhanced chemosensitivity to tamoxifen by negatively regulating OSBPL3 through the RAS signaling pathway in BC cells. Therefore, a treatment strategy based on the miR-181a-5p/OSBPL3 axis may represent a potential approach to overcoming tamoxifen resistance in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.